Revenue GrowthVery strong multi-year revenue growth demonstrates durable commercial traction and expanding market adoption. Sustained top-line expansion improves the company's ability to absorb fixed costs, supports R&D and commercialization spending, and materially reduces execution risk if sustained.

Balance Sheet StrengthA strong equity position and low leverage provide financial flexibility to fund development and operations through losses without urgent refinancing. This capital structure cushions downside risk, supports strategic investments, and lengthens the runway for achieving profitability.

Positive Free Cash FlowConversion to positive free cash flow and operating cash flow signals improving cash generation and operational efficiency. Durable cash generation reduces reliance on external funding, enables reinvestment into growth, and improves resilience during continued path to profitability.

Bears Say

Persistent Net LossesOngoing net losses and negative profit margins are structural concerns that can erode equity over time and constrain strategic choices. Until margins turn positive, the company must either sustain external funding or rely on equity, limiting long-term financial flexibility and shareholder returns.

Earnings Quality / Cash ConversionA low operating-cash-to-net-income ratio indicates earnings (or loss) do not fully translate to cash, raising concerns about quality and sustainability of reported performance. This mismatch can mask underlying working capital or non-cash items that may stress liquidity if trends reverse.

Small Scale / Limited HeadcountA small workforce constrains internal capacity for R&D, regulatory work, manufacturing scale-up and sales execution. Limited human resources increase reliance on partnerships and outsourcing, elevating execution risk and slowing speed-to-market during critical commercialization phases.

4888 FAQ

What was STELLA PHARMA CORPORATION’s price range in the past 12 months?

STELLA PHARMA CORPORATION lowest stock price was ¥200.00 and its highest was ¥505.00 in the past 12 months.

What is STELLA PHARMA CORPORATION’s market cap?

STELLA PHARMA CORPORATION’s market cap is ¥14.91B.

When is STELLA PHARMA CORPORATION’s upcoming earnings report date?

STELLA PHARMA CORPORATION’s upcoming earnings report date is Aug 12, 2026 which is in 170 days.

How were STELLA PHARMA CORPORATION’s earnings last quarter?

STELLA PHARMA CORPORATION released its earnings results on Feb 12, 2026. The company reported -¥6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.

Is STELLA PHARMA CORPORATION overvalued?

According to Wall Street analysts STELLA PHARMA CORPORATION’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does STELLA PHARMA CORPORATION pay dividends?

STELLA PHARMA CORPORATION does not currently pay dividends.

What is STELLA PHARMA CORPORATION’s EPS estimate?

STELLA PHARMA CORPORATION’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does STELLA PHARMA CORPORATION have?

STELLA PHARMA CORPORATION has 34,034,100 shares outstanding.

What happened to STELLA PHARMA CORPORATION’s price movement after its last earnings report?

STELLA PHARMA CORPORATION reported an EPS of -¥6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.814%.

Which hedge fund is a major shareholder of STELLA PHARMA CORPORATION?

Currently, no hedge funds are holding shares in JP:4888

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

STELLA PHARMA CORPORATION

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.